In the dynamic landscape of pharmaceuticals, the UK finds itself at a crossroads, grappling with a decline in pharmaceutical investment, research and development, and clinical trials. The latest Pharmaceutical Competitiveness Framework, a collaboration between the ABPI and PwC, sheds light on the UK’s slipping position in the global pharmaceutical arena. By benchmarking the UK against its peers across 48 indicators, the analysis reveals a significant weakening of the country’s standing since 2018.
One of the glaring statistics is the deceleration of pharmaceutical R&D growth in the UK, which has slowed to a mere 1.9% annually from 2020. This figure pales in comparison to the global average of 6.6%, indicating a concerning trend. Furthermore, foreign direct investment in the UK pharmaceutical sector has mirrored this decline, plummeting from £1.89 billion in 2017 to £795 million in 2023—a staggering 58% decrease. Consequently, the UK’s international ranking has slipped from second place in 2017 and 2021 to seventh in 2023, painting a sobering picture of the country’s competitiveness on the global stage.
Despite these challenges, the UK boasts a robust life sciences foundation, with 16 of the world’s top 100 universities in life sciences and medicine situated within its borders. Additionally, the country is bolstered by cutting-edge infrastructure such as the UK Biobank, the Francis Crick Institute, and the Laboratory of Molecular Biology, underscoring its potential for leadership in the development of innovative medicines and vaccines.
Richard Torbett, Chief Executive of ABPI, emphasizes the urgency of fostering a more competitive environment to attract investment, stating, “The UK has a world-class science base and the potential to lead globally in developing the next generation of medicines and vaccines. But without a more competitive environment for investment, we risk losing out to other countries making bold moves to attract internationally mobile investment.”
The report highlights several barriers hindering the UK’s competitiveness, including the country’s relatively low allocation of healthcare spending to medicines—just 9% compared to 20% in Japan and 17% in Spain. Moreover, only 37% of new medicines are fully accessible in the UK, a stark contrast to Germany where 90% of new medicines are available. This discrepancy has resulted in delays or non-launches of over 60 medicines or indications between 2019/20 and 2022/23, underscoring the need for systemic improvements.
To address these challenges and unlock the UK’s potential for growth in pharmaceuticals, stakeholders emphasize the importance of sustained commitment and decisive action. Russell Abberley, President of ABPI and VP & General Manager at Amgen, stresses the necessity of overcoming the identified issues to realize the full benefits of a thriving life sciences ecosystem for patients and the UK economy.
Moving forward, creating a commercial environment that incentivizes pharmaceutical innovation and expedites patient access to cutting-edge treatments is paramount. By unlocking additional investment in early-stage R&D, facilitating access to clinical trials, and attracting capital investment in R&D and manufacturing facilities, the UK can align with its health and growth objectives, fostering a healthcare landscape that prioritizes innovation and patient outcomes.
In conclusion, the challenges faced by the UK pharmaceutical sector underscore the need for strategic interventions to revitalize its competitiveness on the global stage. By leveraging its scientific excellence, investing in innovative research, and fostering a supportive regulatory environment, the UK can reclaim its position as a key player in the pharmaceutical industry, driving advancements in healthcare and economic growth.
Takeaways:
– The UK pharmaceutical sector faces challenges in investment, R&D, and clinical trials, necessitating strategic interventions.
– Strengthening the country’s competitiveness requires increased healthcare spending on medicines and improved access to innovative treatments.
– Stakeholders emphasize the importance of sustained commitment and decisive action to unlock the full potential of the UK’s life sciences ecosystem.
– Creating a commercial environment that rewards pharmaceutical innovation and accelerates patient access to cutting-edge therapies is crucial for driving growth and improving patient outcomes.